Portola Pharmaceuticals, a biopharmaceutical company, has announced new clinical data that demonstrate PRT060128, the company's novel anti-platelet drug that directly and reversibly inhibits the P2Y12 ADP receptor, overcomes high platelet reactivity in patients who do not respond to clopidogrel.

Portola Pharmaceuticals, a biopharmaceutical company, has started patient enrollment in a large Phase II clinical trial of betrixaban, the company's novel oral Factor Xa inhibitor anticoagulant, for stroke prevention in patients with atrial fibrillation.

Portola Pharmaceuticals has initiated a Phase II clinical trial of the intravenous formulation of PRT060128 in patients experiencing an ST-segment elevation myocardial infarction, a type of heart attack.

Portola Pharmaceuticals has initiated a phase II clinical trial with its oral factor Xa inhibitor for the prevention of deep vein thrombosis and pulmonary embolism in patients undergoing knee replacement surgery.